Biomedical subjects

S Mastroviti

Publications and source records attributed to S Mastroviti.

4 recordsLinked to original sources

PubMed1977

[Pharmacokinetic and clinical research on a new antibiotic combination (amoxicillin and flucloxacillin in equivalent-weight dose)].

A controlled double-blind biometric and an open clinical trial were conducted to determine the therapeutic effectiveness of a new equal-dose w/w association of amoxicillin and flucloxacillin. The following conclusions were drawn. Both antibiotics were present in high serum levels; those of flucloxacillin were higher and more persistent. Analysis of variance on 89 patients pointed to the superiority of the association by comparison with amoxicillin alone. The clinical study made it clear that the broad and complementary spectrum of the association, its synergy, absence of toxicity and good gastric tolerance make it a valuable and effective therapeutic aid, also in presence of germs that produce beta-lactase.

Administration, Oral↗

PubMed1977

[Pharmacokinetics and clinical aspects of a new ampicillin].

The chemical, physical, kinetic features, spectrum and clinical employment of amoxicillin (alpha-amino-p-hydroxbenzylpenicillin) are described. A kinetic study on 48 volunteers indicated its rapid gastroenteric absorption. In addition, the new drug quickly reached serum levels that were able double those obtained with corresponding ampicillin doses of equal weight. A very satisfactory therapeutic response and no more than trivial side-effects were noted in a clinical trial on 106 patients, most of whom presented bacterial infection of the upper and lower airways.

Adult↗

PubMedDate not supplied

[The in-vitro action of amoxicillin on 87 strains of Staphylococcus aureus of 1st isolation].

In vitro activity of Amoxycillin towards 87 strains of Staphilococcus aureus clinically isolated was analyzed. The 70% of the strains were very sensitive to the antibiotic action. Moreover the growth of the 50% of the strains was inhibited by Amoxycillin concentrations less than 0.20 mcg/ml.

Amoxicillin↗

PubMedDate not supplied

[Flucloxacillin].

The pharmacological and clinical properties of flucloxacillin, a new isoxazolilpenicillin, are reported. This drug shows a low acute and chronic toxicity, and enteric absorption clearly higher than cloxacillin and oxacillin. Its binding capability with serum proteins, though rather high, is nevertheless lower than dicloxacillin. The antibacteric activity of flucloxacillin is particularly evident in Gram-positive bacteria and above all on penicillinases producing staphylococci. Flucloxacillin has proved to have successfull effect in the clinical therapy of several infections, particularly of respiratory apparatus and soft tissues.

Animals↗